Seven Deaths This Year Blamed on EpiPens

Comments (0)

Defective EpiPens have been blamed for seven deaths this year and 35 additional hospitalizations. EpiPens contain the hormone epinephrine (also known as adrenaline), which can be used to fight off allergic reactions that can kill. From January through mid-September, the FDA received a total of 228 reports of EpiPen failures.

EpiPens have been under fire lately. EpiPens are sold by a company based in the Netherlands but operated from Pennsylvania. Last year, the company raised the price of an EpiPen from $50 for one pen to $600 for two pens. Government agencies investigated the price increase and another company sued. Thus far, the company has denied any wrongdoing.

In addition to the huge increase in price, earlier this year the company recalled some defective units. The company alleged the defect was extremely rare. However, there have been reports of malfunctions of EpiPens dating back to 2014. The company says that the EpiPen is safe, and there are no identified units with any defects. FDA investigators have reported that in some of the EpiPens, the epinephrine had leaked out, and in other pens the injectors did not work properly. Considering that an EpiPen is a product that is used to save a life in an emergency, any failure is significant.

Many drug manufacturers and medical device manufacturers choose to ignore issues when they arise. They feel that it may be cheaper in the long run to settle with consumers who are harmed than it would be to issue a recall. Sadly, that can result in unnecessary deaths or serious personal injuries to consumers.

If you have been harmed by a defective drug or a defective medical device, call the Houston personal injury attorneys at Kennedy Hodges at 855-947-0707. We can help with your case. Call us today to learn more, or visit us on Twitter to learn more about the firm.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.